ADJUVANT GOSERELIN IN PRE-MENOPAUSAL PATIENTS WITH EARLY BREAST CANCER: RESULTS FROM THE ZIPP STUDY
https://doi.org/10.17650/1994-4098-2009-0-1-2-34-41
Abstract
The Zoladex In Pre-menopausal Patients (ZIPP) study was designed to determine whether addition of goserelin (‘Zoladex’) and/or tamoxifen to adjuvant therapy (radiotherapy and/or chemotherapy), provided benefit to pre- or peri-menopausal women with operable, early breast cancer.
About the Authors
M. Baum
Department of Surgery, University College London, Institute of Surgical Studies, 67—73 Riding House Street, Charles Bell House, London W1W 7EJ
United Kingdom
United Kingdom
A. Hackshaw
Cancer Research UK & UCL Cancer Trials Centre, University College London
United Kingdom
United Kingdom
J. Houghtona
ZIPP International Collaborators' Group
United Kingdom
United Kingdom
L. E. Rutqvist
Stockholm Breast Cancer Study Group
Sweden
Sweden
T. Fornander
Stockholm Breast Cancer Study Group
Sweden
Sweden
B. Nordenskjold
South-East Sweden Breast Cancer Group
Sweden
Sweden
A. Nicolucci
Gruppo Interdisciplinare Valutazione Interventi in Oncologia
Italy
Italy
R. Sainsburya
Department of Surgery, University College London, Institute of Surgical Studies, 67—73 Riding House Street, Charles Bell House, London W1W 7EJ
United Kingdom
United Kingdom
References
1. Kelsey J.L., Bernstein L. Epidemiology and prevention of breast cancer. Annu Rev Public Health 1996;17:47—67.
2. Hankinson S.E., Willett W.C., Colditz G.A. et al. Circulating concen- trations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998;351:1393—6.
3. Poikonen P., Saarto T., Elomaa I. et al. Prognostic effect of amenorrhoea and elevated serum gonadotropin levels induced by adjuvant chemotherapy in premenopausal node-positive breast can- cer patients. Eur J Cancer 2000;36:43—8.
4. Early Breast Cancer Trialists' Collaborative Group. Ovarian ablation in early breast cancer: overview of the ran- domised trials. Lancet 1996;348:1189—96.
5. Nystedt M., Berglund G., Bolund C. et al. Side-effects of adjuvant endocrine treatment in pre-menopausal breast can- cer patients: a prospective randomised study. J Clin Oncol 2003;21:1836—44.
6. International Breast Cancer Study Group (IBCSG). Adjuvant chemothera- py followed by goserelin versus either modality alone for pre-menopausal lymph nodenegative breast cancer: a ran- domised trial. JNCI 2003;95:1833—46.
7. Kaufmann M., Jonat W., Blamey R. et al. on behalf of the Zoladex Early Breast Cancer Research Association (ZEBRA) Trialists' Group. Eur J Cancer 2003;39:1711—7.
8. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the ran- domised trials. Lancet 1998;351:1451—67.
9. Pagani O., O'Neill A., Castiglione M. et al. Prognostic impact of amenorrhoea after adjuvant chemotherapy in pre- menopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer 1998;34:632—40.
10. Poikonen P., Saarto T., Elomaa I. et al. Prognostic effect of amenorrhoea and elevated serum gonadotropin levels induced by adjuvant chemotherapy in pre-menopausal node-positive breast cancer patients. Eur J Cancer 2000;36:43—8.
11. Davidson N.E., O'Neill A.M., Vukov A.M. et al. Chemoendocrine ther- apy for premenopausal women with axil- lary lymph nodepositive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). J Clin Oncol 2005;23(25):5973—82.
12. Goldhirsch A., Glick J.H., Gelber R.D. et al. Meeting highlights: international consensus panel on the treatment of primary breast cancer. sev- enth international conference on adju- vant therapy of primary breast cancer. J Clin Oncol 2001;19:3817—27.
13. NIH Consensus Development Panel. J Natl Cancer Inst 2001;93:979—89.
Review
For citations:
Baum M., Hackshaw A., Houghtona J., Rutqvist L.E., Fornander T., Nordenskjold B., Nicolucci A., Sainsburya R. ADJUVANT GOSERELIN IN PRE-MENOPAUSAL PATIENTS WITH EARLY BREAST CANCER: RESULTS FROM THE ZIPP STUDY. Tumors of female reproductive system. 2009;(1-2):34-41. (In Russ.) https://doi.org/10.17650/1994-4098-2009-0-1-2-34-41
Views:
742
Email this article 